title: Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.
abstract: BACKGROUND
  In atopic asthma there is strong evidence of eosinophils playing an active role in pathogenesis. Some investigations demonstrated that eosinophil cationic protein (ECP) serum levels increased in atopic patients with asthma during pollen season.
  
  
  OBJECTIVE
  The aim of the study was to evaluate the effects of short-term (1 week) beta 2-agonist treatment on lung function and eosinophil activity in asthmatic patients.
  
  
  METHODS
  We used an open, randomized, cross-over design to compare the effects of salbutamol (200 micrograms q.i.d.) and salmeterol (50 micrograms b.i.d.) on peak expiratory flow rate (PEFR), blood eosinophil count and serum levels of ECP as a measure of eosinophil activity in 20 mild atopic asthmatics.
  
  
  RESULTS
  Morning and evening PEFR values were both significantly higher during salmeterol treatment than during the salbutamol period. Conversely, both morning and evening daily asthma symptom scores were significantly lower during salmeterol treatment compared with those recorded during the salbutamol period. The mean basal eosinophil blood count on salmeterol treatment (601 +/- 189 mm3) was not higher than the mean count on salbutamol treatment (612 +/- 204 mm3). After both treatments the mean eosinophil blood counts were unchanged (619 +/- 189 mm3 and 576 +/- 212 mm3, respectively). No significant differences in blood eosinophil counts were observed between or within treatments at any time. No significant difference was observed in baseline mean ECP serum concentration (43.8 +/- 26.3 micrograms/L on salmeterol treatment and 41.7 +/- 29.8 micrograms/L on salbutamol treatment, respectively). After salmeterol treatment the mean ECP serum concentration had fallen significantly to 20.9 +/- 18.6 micrograms/L (P < 0.01), whereas after salbutamol treatment it was unchanged (42.0 +/- 25.1 micrograms/L). Salmeterol treatment produced a decrease in ECP serum levels without any changes in blood eosinophil count.
  
  
  CONCLUSIONS
  This study demonstrates that salmeterol affords a significant improvement in asthma control during the pollen season, measured by both subjective and objective parameters, compared with salbutamol. This greater efficacy may be related to inhibition of eosinophil degranulation during the pollen season.
authors.affiliation: Istituto di Medicina Interna e Geriatria, Università degli Studi di Palermo, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Di Lorenzo
authors.forename: G
authors.initials: G
authors.lastname: Morici
authors.forename: F
authors.initials: F
authors.lastname: Norrito
authors.forename: P
authors.initials: P
authors.lastname: Mansueto
authors.forename: M
authors.initials: M
authors.lastname: Melluso
authors.forename: F
authors.initials: F
authors.lastname: Purello D'Ambrosio
authors.forename: G
authors.initials: G
authors.lastname: Barbagallo Sangiorgi
mesh_terms: D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001798:Blood Proteins / Q000187:drug effects* / Q000378:metabolism; D002452:Cell Count; D018592:Cross-Over Studies; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D011058:Pollen / Q000166:cytology / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000209:etiology / Q000503:physiopathology; D012260:Ribonucleases; D000068299:Salmeterol Xinafoate
chemical_list: D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D000068299:Salmeterol Xinafoate; D012260:Ribonucleases; D000420:Albuterol